Global Fragile X Syndrome Market 2027: Top Key Players Marinus pharmaceuticals, Ovid therapeutics, Kareus Therapeutics, Bellus health Inc., AMO pharmaceuticals, Eli Lilly & Company, Neuren pharmaceuticals, Anavex Life Sciences Corp., and Zynerba Pharmaceu

Fragile X syndrome is a hereditary condition that causes a range of neurological problems including cognitive impairment and learning disabilities. Males are more affected compare to females by this disorder. It causes delayed development of speech and language by age 2. Affected children may develop attention deficit disorder; about one-third individual may develop autism, and in about 15% of male and 5% of female seizure occurs. Most males and about half of females with fragile X syndrome have characteristic physical features that become more prominent with age. These features include large ears, a long and narrow face, unusually flexible fingers, flat feet, a prominent jaw and forehead, and in males, enlarged testicles after puberty. It is estimated that approximately 1 in 2500-4000 males and 1 in 7000-8000 females.

Request For Sample @ https://bit.ly/2VzpB42

The global Fragile X syndrome market is segmented on the basis of treatment and geography. On the basis of treatment the global Fragile X syndrome is further segmented into sedatives, muscle relaxants, antipsychotics, and other. Currently there is no approved treatment for Fragile X Syndrome, however treatment and intervention are focused to improve lives of affected individuals. Majority of pipeline molecules (gaboxadol, etc.) for the treatment of Fragile X Syndrome are currently in phase 2 of development are expected to come into the market in forecast period. Increase in incidence and prevalence of Fragile X Syndrome expected to boost the growth of the market in forecast period. In addition to it, ongoing clinical trials and growing licensing and acquisition deals will further drives the growth of the market. However, stringent government regulation, complex disease mechanism, and disappointing results of promising pipeline molecules hampers the growth of the Fragile X syndrome market during forecast period. Furthermore, lack of awareness among people regarding genetic disorders restrains the growth of the market.

At regional level, the global Fragile X syndrome market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global Fragile X syndrome market. This is because strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities for the Fragile X syndrome market.

Request For Table Of Content (TOC) @ https://bit.ly/2VzpB42

Some of the market players leading the global Fragile X syndrome market include Marinus pharmaceuticals, Ovid therapeutics, Kareus Therapeutics, Bellus health Inc., AMO pharmaceuticals, Eli Lilly & Company, Neuren pharmaceuticals, Anavex Life Sciences Corp., and Zynerba Pharmaceuticals, Inc.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.